Wave life sciences reports second quarter 2023 financial results and provides business update

Preparing for imminent submission of clinical trial applications (ctas) for galnac-conjugated aatd candidate (wve-006), the industry's first rna editing clinical candidate

WVE Ratings Summary

WVE Quant Ranking